Anita Mamtani1, Julie J Gonzalez1, Dayna Neo2, Priscilla J Slanetz3, Mary Jane Houlihan1, Christina I Herold4, Abram Recht5, Michele R Hacker2, Ranjna Sharma6. 1. Breast Service, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA. 2. Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 3. Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 4. Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 5. Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 6. Breast Service, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA. rsharma1@bidmc.harvard.edu.
Abstract
BACKGROUND: Nodal staging with sentinel node biopsy (SLNB), post-lumpectomy radiotherapy (RT), and endocrine therapy (ET) for estrogen receptor-positive (ER+) tumors is valuable in the treatment of early-stage (stages 1 or 2) breast cancer but used less often for elderly women. METHODS: This retrospective study investigated women referred for surgical evaluation of biopsy-proven primary early-stage invasive breast cancer from January 2001 to December 2010. Clinicopathologic features, treatment course, and outcomes for women ages 80-89 years and 50-59 years were compared. RESULTS: The study identified 178 eligible women ages 80-89 years and 169 women ages 50-59 years. The elderly women more often had grade 1 or 2 disease (p = 0.003) and ER+ tumors (p = 0.007) and less frequently had undergone adjuvant therapies (all p ≤ 0.001). Lumpectomy was performed more commonly for the elderly (92 vs. 83 %, p = 0.02), and axillary surgery was less commonly performed (46 vs. 96 %; p < 0.001). Fewer elderly women had undergone post-lumpectomy RT (42 vs. 89 %; p < 0.001) and ET for ER+ tumors (72 vs. 95 %; p < 0.001). During the median follow-up period of 56 months for the 80- to 89-year old group and 98 months for the 50- to 59-year-old group, death from breast cancer was similar (4 vs. 5 %; p = 0.5). The two groups respectively experienced 7 versus 6 locoregional recurrences and 11 versus 13 distant recurrences. CONCLUSIONS: The octogenarians had disease survivorship similar to that of the younger women despite less frequent use of adjuvant therapies, likely reflecting lower-risk disease features. Whether increased use of axillary surgery, post-lumpectomy RT, and/or ET for ER+ tumors would further improve outcomes is an important area for further study, but treatment should not be deferred solely on the basis of age.
BACKGROUND: Nodal staging with sentinel node biopsy (SLNB), post-lumpectomy radiotherapy (RT), and endocrine therapy (ET) for estrogen receptor-positive (ER+) tumors is valuable in the treatment of early-stage (stages 1 or 2) breast cancer but used less often for elderly women. METHODS: This retrospective study investigated women referred for surgical evaluation of biopsy-proven primary early-stage invasive breast cancer from January 2001 to December 2010. Clinicopathologic features, treatment course, and outcomes for women ages 80-89 years and 50-59 years were compared. RESULTS: The study identified 178 eligible women ages 80-89 years and 169 women ages 50-59 years. The elderly women more often had grade 1 or 2 disease (p = 0.003) and ER+ tumors (p = 0.007) and less frequently had undergone adjuvant therapies (all p ≤ 0.001). Lumpectomy was performed more commonly for the elderly (92 vs. 83 %, p = 0.02), and axillary surgery was less commonly performed (46 vs. 96 %; p < 0.001). Fewer elderly women had undergone post-lumpectomy RT (42 vs. 89 %; p < 0.001) and ET for ER+ tumors (72 vs. 95 %; p < 0.001). During the median follow-up period of 56 months for the 80- to 89-year old group and 98 months for the 50- to 59-year-old group, death from breast cancer was similar (4 vs. 5 %; p = 0.5). The two groups respectively experienced 7 versus 6 locoregional recurrences and 11 versus 13 distant recurrences. CONCLUSIONS: The octogenarians had disease survivorship similar to that of the younger women despite less frequent use of adjuvant therapies, likely reflecting lower-risk disease features. Whether increased use of axillary surgery, post-lumpectomy RT, and/or ET for ER+ tumors would further improve outcomes is an important area for further study, but treatment should not be deferred solely on the basis of age.
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Mara A Schonberg; Edward R Marcantonio; Donglin Li; Rebecca A Silliman; Long Ngo; Ellen P McCarthy Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Willemien van de Water; Caroline Seynaeve; Esther Bastiaannet; Christos Markopoulos; Steve E Jones; Daniel Rea; Annette Hasenburg; Hein Putter; Elysée T M Hille; Robert Paridaens; Anton J M de Craen; Rudi G J Westendorp; Cornelis J H van de Velde; Gerrit-Jan Liefers Journal: Oncologist Date: 2012-12-20
Authors: Penny Fang; Weiguo He; Daniel R Gomez; Karen E Hoffman; Benjamin D Smith; Sharon H Giordano; Reshma Jagsi; Grace L Smith Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-01 Impact factor: 7.038
Authors: Courtney P Williams; Kelly M Kenzik; Andres Azuero; Grant R Williams; Maria Pisu; Karina I Halilova; Stacey A Ingram; Supriya K Yagnik; Andres Forero; Smita Bhatia; Gabrielle B Rocque Journal: Oncologist Date: 2018-08-17
Authors: Margaret E Smith; C Ann Vitous; Tasha M Hughes; Sarah P Shubeck; Reshma Jagsi; Lesly A Dossett Journal: Ann Surg Oncol Date: 2020-03-02 Impact factor: 5.344
Authors: Ye Won Jeon; Sun Hyong You; Jong Eun Lee; Hyun Jo Youn; Woosung Lim; Jai Hong Han; Chan Heun Park; Yong Seok Kim Journal: Breast Cancer Res Treat Date: 2019-09-06 Impact factor: 4.872